Myles Walsh
Executive Director, Business Development Predicine
Seminars
Wednesday 9th September 2026
Advancing RAS-Targeted Drug Development with Ultra-Deep Genomics, Personalized MRD, and Multi-Omic Resistance Monitoring
4:00 pm
- Advancing from standard to ultra-deep ctDNA molecular profiling to expand patient identification and enrollment, enable therapy response monitoring, support global clinical trials, and accelerate the next-generation CDx assay development
- Applying personalized, clinically actionable MRD assay to monitor molecular response, detect residual disease, and identify emerging RAS-pathway resistance mechanisms
- Expanding beyond genomics through epigenomic and transcriptomic liquid biopsy approaches to provide functional insights into tumor biology, therapy response, and rational combination treatment strategies
